Semaglutide
Semaglutide is used in several prescription products. Oral and injectable formulations have different schedules, and starting amounts are separate from maintenance treatment.
Technical catalog description
Semaglutide is a long-acting GLP-1 receptor agonist that has transformed pharmaceutical weight-management. By slowing gastric emptying, improving insulin sensitivity and crushing appetite, it allows users to maintain deep calorie deficits with minimal hunger or stimulant use.
Read next
Mechanism details
Semaglutide activates the GLP-1 receptor. Approved products are used for specific medical indications, including diabetes and weight management. The product, indication, formulation, and route determine which prescribing information applies.
Nausea, reflux, constipation, reduced appetite, and dehydration
Gallbladder issues or lean-mass loss if the user under-eats protein and fluids
bodyweight trend
hydration status
fasting glucose / HbA1c if used for metabolic control
History of severe GI intolerance, pancreatitis concerns, or inability to stay hydrated
Using it while ignoring protein intake and resistance training
Product and formulation
A compound name alone does not identify a treatment schedule. Wegovy prescribing information covers both injectable and oral formulations. Their amounts and schedules are different, and they are not interchangeable by converting the units alone.
This profile does not establish a universal starting amount, escalation schedule, or maintenance amount. Consult the prescribing information for the exact product and discuss treatment with a clinician. Research products and compounded preparations should not be assumed equivalent to an approved product.
Effects and risks
Semaglutide can reduce appetite and affect blood glucose. Nausea, vomiting, diarrhea, constipation, and abdominal pain are among the adverse reactions described in the Wegovy label. The label also includes warnings concerning pancreatitis, gallbladder disease, dehydration-related kidney injury, and severe gastrointestinal reactions. Hypoglycemia risk can increase when it is used with insulin or certain other diabetes medicines.
The boxed warning concerns thyroid C-cell tumors observed in rodents; whether these occur in humans is unknown. Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Reference limits
Weight-loss results and treatment timelines depend on the studied product, population, and treatment conditions. This catalog does not provide a personalized weight-loss forecast or a regimen for performance use. Saving a quantity in the builder records what was entered; it does not establish that the quantity is appropriate or safe.
Source
Wegovy prescribing information, reviewed for product and formulation distinctions and labeled safety information.
Source reference information
Product-specific starting stages · oral or injection. Product, route, indication and treatment stage select the applicable reference; no generic semaglutide regimen. References remain separate from quantities entered in a plan.
Starting: 0.25 mg/administration. Once weekly. Wegovy injection initiation stage. Population: Adults meeting labeled weight-management indications. Route: subcutaneous; formulation: Wegovy injection. Source duration: First 4 weeks before labeled escalation. Starting stage only, not maintenance. Not interchangeable with oral semaglutide, other brands or unverified compounded concentrations. Source: Wegovy prescribing information.
Starting: 1.5 mg/day total. Once daily. Wegovy tablet initiation stage. Population: Adults meeting labeled weight-management indications. Route: oral; formulation: Wegovy tablet. Source duration: First 30 days before labeled escalation. Different route and schedule from injection. Label has specific fasting/water/waiting instructions; this abbreviated reference is not the complete label. Source: Wegovy prescribing information.